Twice-per-weekSelinexor, 2 Days Melphalan

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Selinexor

Selinexor: 60 mg/day from days -9 to -5.

DRUG

Melphalan

Selinexor: 60 mg/day from days -9 to -5.

DRUG

Intravenous Busulfan

3.2 mg/kg on days

DRUG

Fludarabine

30 mg/m² on days

Trial Locations (4)

450000

Zhengzhou University First Affiliated Hospital, Zhengzhou

610083

People's Liberation Army The General Hospital of Western Theater Command, Chengdu

05000

Hebei Medical University Second Hospital, Shijiazhuang

Unknown

The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army, Jinan

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER